دورية أكاديمية
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
| العنوان: | Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
|---|---|
| المؤلفون: | Backhaus, Donata, Jentzsch, Madlen, Bischof, Lara, Brauer, Dominic, Wilhelm, Christina, Schulz, Julia, Franke, Georg-Nikolaus, Pönisch, Wolfram, Vucinic, Vladan, Platzbecker, Uwe, Schwind, Sebastian |
| حالة النشر: | publishedVersion |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Original Material: | urn:nbn:de:bsz:15-qucosa2-849897 |
| مصطلحات موضوعية: | trisomy 8, AML, allogeneic HSCT, MRD, info:eu-repo/classification/ddc/610, ddc:610 |
| الوصف: | Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogeneic HSCT have not been performed so far. Methods: We retrospectively analyzed clinical features, outcomes, and measurable residual disease (MRD) of 659 AML (12%, n = 81, with a trisomy 8) patients subjected to allogeneic HSCT as a consolidation therapy. Results: The presence of a trisomy 8 associated with a trend for higher age at diagnosis, AML of secondary origin, lower white blood cell counts at diagnosis, worse ELN2017 genetic risk, wild-type NPM1, and mutated IDH1/2 and JAK2. Outcomes after allogeneic HSCT in the entire cohort did not differ between patients with a sole trisomy 8, trisomy 8 with additional cytogenetic aberrations or without a trisomy 8. A trisomy 8 did not affect outcomes within the three ELN2017 risk groups. In accordance with findings in unselected patient cohorts, persistent MRD at allogeneic HSCT in patients with a trisomy 8 identified individuals with a higher risk of relapse following allogeneic HSCT. Conclusions: Outcomes of trisomy 8 patients after allogeneic HSCT did not compare unfavorably to that of other AML patients following allogeneic HSCT. Rather than the presence or absence of a trisomy 8, additional genetic aberrations and MRD at HSCT define outcome differences and aid in informed treatment decisions. |
| Original Identifier: | oai:qucosa:de:qucosa:84989 |
| نوع الوثيقة: | Article |
| اللغة: | English |
| تدمد: | 2072-6694 |
| العلاقة: | 5679 |
| الإتاحة: | https://ul.qucosa.de/id/qucosa%3A84989Test https://ul.qucosa.de/api/qucosa%3A84989/attachment/ATT-0Test/ |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsndl.DRESDEN.oai.qucosa.de.qucosa.84989 |
| قاعدة البيانات: | Networked Digital Library of Theses & Dissertations |
Full Text Finder | تدمد: | 20726694 |
|---|